ADB-5'Br-BUTINACA

Synthetic cannabinoid

ADB-5'Br-BUTINACA is a synthetic cannabinoid that has been identified in various recreational drug products. It is a potent agonist of the cannabinoid receptors, which are part of the endocannabinoid system in the human body.

Chemical Structure and Properties

Structure of ADB-5'Br-BUTINACA

ADB-5'Br-BUTINACA is chemically classified as an indazole-based synthetic cannabinoid. Its structure includes a bromine atom at the 5' position, which distinguishes it from other similar compounds. The presence of the bromine atom is thought to influence its binding affinity and potency at the cannabinoid receptors.

The chemical formula of ADB-5'Br-BUTINACA is C20H28BrN3O2, and it has a molecular weight of 422.36 g/mol. The compound is typically found as a white powder and is often dissolved in solvents for application onto plant material.

Pharmacology

ADB-5'Br-BUTINACA acts as a full agonist at the CB1 receptor and CB2 receptor, which are the primary receptors of the endocannabinoid system. These receptors are involved in a variety of physiological processes, including pain sensation, mood regulation, and appetite control.

The potency of ADB-5'Br-BUTINACA at these receptors is significantly higher than that of Δ9-tetrahydrocannabinol (THC), the main psychoactive component of cannabis. This increased potency can lead to more pronounced effects and a higher risk of adverse reactions.

Legal Status

The legal status of ADB-5'Br-BUTINACA varies by country. In many jurisdictions, it is classified as a controlled substance due to its potential for abuse and lack of accepted medical use. Regulatory agencies often place synthetic cannabinoids like ADB-5'Br-BUTINACA under temporary or permanent bans to prevent their distribution and use.

Health Effects and Risks

The use of ADB-5'Br-BUTINACA has been associated with a range of adverse health effects. Users may experience symptoms such as tachycardia, hypertension, nausea, vomiting, anxiety, and hallucinations. In severe cases, use can lead to seizures, psychosis, and even death.

The variability in the composition of products containing synthetic cannabinoids further complicates the risk assessment, as users may be exposed to unknown and potentially harmful substances.

Detection and Analysis

ADB-5'Br-BUTINACA can be detected in biological samples using advanced analytical techniques such as gas chromatography-mass spectrometry (GC-MS) and liquid chromatography-tandem mass spectrometry (LC-MS/MS). These methods allow for the identification and quantification of the compound in blood, urine, and other matrices.

Related Pages

• Synthetic cannabinoids
• Cannabinoid receptor
• Endocannabinoid system
• Drug policy